Zhuang, C., Liu, X., Song, Y., He, P., Zheng, D., Yan, X., Zhong, X., Tian, T., Wei, B., Xie, Y. X., Chen, J., Lv, Q., Luo, T. (2025). Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e12623